Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16980137 | 0.90 | TAAR1 (0.47) | TAAR1AOC3KMT2AHTR6USP2 | |
| SCHEMBL15568063 | 0.84 | KMT2A (0.57) | KMT2ALMNAPOLB | |
| SCHEMBL26810022 | 0.82 | RECQL (0.42) | KMT2AHTR6POLBTDP1 | |
| SCHEMBL15599508 | 0.82 | KMT2A (0.40) | TAAR1KMT2AHTR6POLB | |
| SCHEMBL16971182 | 0.82 | TAAR1 (0.53) | TAAR1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL775451 | 0.81 | LMNA (0.44) | TAAR1KMT2AUSP2LMNANPSR1 | |
| SCHEMBL15599406 | 0.80 | TAAR1 (0.58) | TAAR1KMT2AHTR6L3MBTL1 | |
| SCHEMBL14426959 | 0.79 | KMT2A (0.43) | KMT2AUSP2LMNANPSR1TP53 | |
| SCHEMBL422010 | 0.78 | USP2 (0.51) | TAAR1KMT2AUSP2LMNANPSR1 | |
| SCHEMBL9261232 | 0.77 | TAAR1 (0.52) | TAAR1AOC3KMT2APOLBAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2882727-B1 | IMMUNOMODULATORY COMPOUNDS | UNIV STRATHCLYDE (GB) | 2021-01-20 | — | — | EP | disclosed |
| US-9598386-B2 | Immunomodulatory compounds | UNIVERSITY OF STRATHCLYDE (GB) | 2017-03-21 | — | — | US | disclosed |
| US-9598386-B2 | Immunomodulatory compounds | UNIVERSITY OF STRATHCLYDE (GB) | 2017-03-21 | — | — | US | disclosed |
| US-9598386-B2 | Immunomodulatory compounds | UNIVERSITY OF STRATHCLYDE (GB) | 2017-03-21 | — | — | US | disclosed |
| US-20150218116-A1 | Immunomodulatory Compounds | UNIVERSITY OF STRATHCLYDE (GB) | 2015-08-06 | — | — | US | disclosed |
| US-20150218116-A1 | Immunomodulatory Compounds | UNIVERSITY OF STRATHCLYDE (GB) | 2015-08-06 | — | — | US | disclosed |
| US-20150218116-A1 | Immunomodulatory Compounds | UNIVERSITY OF STRATHCLYDE (GB) | 2015-08-06 | — | — | US | disclosed |
| WO-2014023934-A1 | IMMUNOMODULATORY COMPOUNDS | UNIVERSITY OF STRATHCLYDE (GB) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218116-A1 | Immunomodulatory Compounds | TSLP, IL2, ICOS | TAAR1 3321/4885AOC3 3091/4885KMT2A 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.